Clinical significance of Mena and Her-2 expression in breast cancer

Objective: The aim of this study was to determine the expression patterns of Mena and Her-2 in breast cancer tissues and to explore their clinical significance and correlation with clinicopathological parameters. Methods: The expression of Mena and Her-2 was detected in 40 breast cancer tissues and 14 normal breast tissues by immunohistochemistry, and the relationship of Mena and Her-2 expression with clinicopathological parameters was analyzed. Results: Both Mena (70%) and Her-2 (40%) were more commonly expressed in breast cancer than in normal breast tissue (7.1%, 0%, respectively; p < 0.05); further, Mena and Her-2 expression in breast cancer were positively correlated (r = 0.530, p < 0.05). In comparing expression with clinicopathological parameters of tumor samples, Mena and Her-2 were both associated with axillary lymph node metastasis and TNM stage (p < 0.05), but not with patient age or pathological type. Conclusions: Mena and Her-2 are related to the malignancy degree and metastasis of breast cancer, and thus may play a coordinating role in the occurrence and progression of breast cancer.

Breast cancer; Mena; Her-2; Immunohistochemistry; Clinicopathological parameter

[1] Botha J.L., Bray F., Sankila R., Parkin D.M.: “Breast cancer incidence and mortality trends in 16 European countries”. Eur. J. Cancer, 2003, 39, 1718.

[2] DeSantis C., Siegel R., Bandi P., Jemal A.: “Breast cancer statistics, 2011”. CA Cancer J. Clin., 2011, 61, 409.

[3] Long N., Moore M.A., Chen W., Gao C.M., Lai M.S., Mizoue T. et al.: “Cancer epidemiology and control in north-East Asia - past, present and future”. Asian Pac J. Cancer Prev., 2010, 11 (suppl. 2), 107.

[4] Mazurek M.S.: “Sedation and analgesia for procedures outside the operating room”. Semin. Pediatr. Surg., 2004, 13, 166.

[5] Mao J., Hai J., Shu H.P., Wu Y.H., Ou H.Y., Luo S.Y. et al.: “Expressions of survivin and nm23 and the relationship among the expressions and the axillary lymph node metastasis in breast cancer”. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2005, 30, 312.

[6] Liu B.B., Wei J., Fu L.: “Updates on genes related to breast cancer metastasis”. Zhonghua Bing Li Xue Za Zhi, 2008, 37, 266.

[7] Kwiatkowski A.V., Gertler F.B., Loureiro J.J.: “Function and regulation of Ena/VASP proteins”. Trends Cell. Biol., 2003, 13, 386.

[8] Hoffman L.M., Jensen C., Kloeker S., Wang C.L., Yoshigi M., Beckerle M.C.: “Genetic ablation of zyxin causes Mena/VASP mislocalization, increased motility, and deficits in actin remodeling”. J. Cell Bio., 2006, 172, 771.

[9] Di Modugno F., Mottolese M., Di Benedetto A., Conidi A., Novelli F., Perracchio L. et al.: “The cytoskeleton regulatory protein hMena ENAH is overexpressed in human benign breast lesions with high risk of transformation and human epiderma growth factor receptor 2 positive hormonal receptor negative tumors”. Clin. Cancer Res., 2006, 12, 1470.

[10] Milier J.K., Shattuck D.L., Ingalla E.Q., Yen L., Bowowsky A.D., Young L.J. et al.: “Suppression of the negative regulator contributes to ErbB2 overexpression in breast cancer”. Cancer Res., 2008, 68, 8286.

[11] Browne B.C., O’Brien N., Dufly M.J., Crown J., O Donovan N.: “HER-2 signaling and inhibition in breast cancer”. Curr. Drug. Targets, 2009, 9, 419.

[12] Philippar U., Roussos E.T., Oser M., Yamaguchi H., Kim H.D., Giampieri S. et al.: “A Mena invasion isoform potentiates EGFinduced carcinoma cell invasion and metastasis”. Dev. Cell., 2008, 15, 813.

[13] Xu Z.H., Ford B.D.: “Upregulation of erbB receptors in rat brain after middle cerebral arteria occlusion”. Neurosei Lett., 2005, 375, 181.

[14] Wang Y.J., Wang N., Wang B., Qin W.X., Xue C.Y.: “Comparison of clinicopathologic characteristics and prognosis of triple-negative with Her-2-overexpressing breast cancer”. Zhonghua Zhong Liu Za Zhi, 2009, 31, 346.

[15] Spector N.L., Blackwell K.L.: “Understanding the mechanism behind trastuzumab therapy for human epidermal growth factor receptor2 positive breast cancer”. J. Clin. Oncol., 2009, 27, 5838.

[16] Kröger N., Milde-Langosch K., Riethdorf S., Schmoor C., Schumacher M., Zander A.R. et al.: “Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients”. Clin. Cancer Res., 2006, 12, 159.